Table 3.
Baseline characteristics of patients with confirmed laboratory COVID-19 in the NHIS COVID-19 DB.
| Characteristic | Entire Cohort n = 338 |
AAP n = 176 |
NSAIDs n = 162 |
|---|---|---|---|
| Sex, n (%) | |||
| male | 140 (41.4) | 80 (45.5) | 60 (37.0) |
| female | 198 (58.6) | 96 (54.5) | 102 (63.0) |
| Age, n (%) | |||
| 20–29 | 46 (13.6) | 22 (12.5) | 24 (14.8) |
| 30–39 | 31 (9.2) | 18 (10.5) | 13 (8.0) |
| 40–49 | 50 (14.8) | 27 (15.3) | 23 (14.2) |
| 50–59 | 81 (24.0) | 43 (24.4) | 38 (23.5) |
| 60–69 | 66 (19.5) | 27 (15.3) | 39 (24.1) |
| 70–79 | 38 (11.2) | 26 (14.8) | 12 (7.4) |
| 80– | 26 (7.7) | 13 (7.4) | 13 (8.0) |
| Region, n (%) | |||
| Seoul | 26 (7.7) | 13 (7.4) | 13 (8.0) |
| Gyeonggi | 22 (6.5) | 12 (6.8) | 10 (6.2) |
| Daegu | 184 (54.4) | 96 (54.5) | 88 (54.3) |
| Gyeongbuk | 53 (15.7) | 29 (16.5) | 24 (14.8) |
| Others | 53 (15.7) | 26 (14.8) | 27 (16.7) |
| HTN, n (%) | 88 (26.0) | 50 (28.4) | 38 (23.5) |
| COPD, n (%) | 6 (1.8) | 2 (1.1) | 4 (2.5) |
| Asthma, n (%) | 47 (13.9) | 21 (11.9) | 26 (16.0) |
| CKD, n (%) | 12 (3.6) | 6 (3.4) | 6 (3.7) |
| DM, n (%) | 69 (20.4) | 38 (21.6) | 31 (19.1) |
| CVA, n (%) | 24 (7.1) | 12 (6.8) | 12 (7.4) |
| Charlson Comorbidity Index, n (%) | |||
| 0 | 150 (44.4) | 74 (42.0) | 76 (46.9) |
| 1 | 51 (15.1) | 26 (14.8) | 25 (15.4) |
| 2 or more | 137 (40.5) | 76 (43.2) | 61 (37.7) |
| Current use of medication, n (%) | |||
| Steroid | 39 (11.5) | 21 (11.9) | 18 (11.1) |
AAP: acetaminophen; NSAIDs: non-steroidal anti-inflammatory drugs; HTN: hypertension; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; DM: diabetes mellitus; CVA: cerebrovascular disease.